Several nanoscaled systems for cancer therapy are approved or in clinical trials. Here, Davis and colleagues discuss the key properties of nanotherapeutics for cancer, summarize clinical findings with first- and second-generation nanoparticles, and discuss the issues involved in translating experimental nanotherapeutics to the clinic.
- Mark E. Davis
- Zhuo (Georgia) Chen
- Dong M. Shin
